Background: BRAF (v‐raf murine sarcoma viral oncogene homolog B1) and MEK (mitogen activated protein kinase) inhibitors, as well as immunotherapy against cytotoxic T‐lymphocyte-associated antigen 4 (CTLA‐4) and the programmed cell death 1 (PD‐1) receptor and its ligand (PD‐ L1), have shown good results in improving the disease‐free survival of patients with metastatic melanoma (MM). The aim of this review is to summarize the main oral adverse events (oAEs) occurring in patients undergoing target or immunotherapy. We proposed two separate sections: oAEs during the treatment with 1) target therapies with BRAF and MEK inhibitors and tyrosine kinase inhibitors (gingival hyperplasia, pigmentation disorders, squamo‐proliferative lesions) and 2) immunotherapies with CTLA‐4 or PD1 inhibitors (lichenoid reactions, immuno‐bullous reactions, xerostomia and other reactions). Adverse events frequently include oAEs, although these are often misdiagnosed and under‐reported. Indeed, the oral cavity is not routinely evaluated during clinical practice. The symptomatology related to oAEs is significant since it may represent the first manifestation of a severe systemic reaction, possibly leading to difficulties in nutrition with a consequent impact on patients’ quality of life. A careful examination of the oral cavity is recommended during the evaluation of oncologic patients in order to promptly detect the onset of new manifestations.

Oral manifestations in melanoma patients treated with target or immunomodulatory therapies / Dika E.; Lambertini M.; Gouveia B.; Mussi M.; Marcelli E.; Campione E.; Gurioli C.; Melotti B.; Alessandrini A.; Ribero S.. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - ELETTRONICO. - 10:6(2021), pp. 1283.1-1283.11. [10.3390/jcm10061283]

Oral manifestations in melanoma patients treated with target or immunomodulatory therapies

Dika E.
;
Lambertini M.;Mussi M.;Marcelli E.;Gurioli C.;Alessandrini A.;
2021

Abstract

Background: BRAF (v‐raf murine sarcoma viral oncogene homolog B1) and MEK (mitogen activated protein kinase) inhibitors, as well as immunotherapy against cytotoxic T‐lymphocyte-associated antigen 4 (CTLA‐4) and the programmed cell death 1 (PD‐1) receptor and its ligand (PD‐ L1), have shown good results in improving the disease‐free survival of patients with metastatic melanoma (MM). The aim of this review is to summarize the main oral adverse events (oAEs) occurring in patients undergoing target or immunotherapy. We proposed two separate sections: oAEs during the treatment with 1) target therapies with BRAF and MEK inhibitors and tyrosine kinase inhibitors (gingival hyperplasia, pigmentation disorders, squamo‐proliferative lesions) and 2) immunotherapies with CTLA‐4 or PD1 inhibitors (lichenoid reactions, immuno‐bullous reactions, xerostomia and other reactions). Adverse events frequently include oAEs, although these are often misdiagnosed and under‐reported. Indeed, the oral cavity is not routinely evaluated during clinical practice. The symptomatology related to oAEs is significant since it may represent the first manifestation of a severe systemic reaction, possibly leading to difficulties in nutrition with a consequent impact on patients’ quality of life. A careful examination of the oral cavity is recommended during the evaluation of oncologic patients in order to promptly detect the onset of new manifestations.
2021
Oral manifestations in melanoma patients treated with target or immunomodulatory therapies / Dika E.; Lambertini M.; Gouveia B.; Mussi M.; Marcelli E.; Campione E.; Gurioli C.; Melotti B.; Alessandrini A.; Ribero S.. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - ELETTRONICO. - 10:6(2021), pp. 1283.1-1283.11. [10.3390/jcm10061283]
Dika E.; Lambertini M.; Gouveia B.; Mussi M.; Marcelli E.; Campione E.; Gurioli C.; Melotti B.; Alessandrini A.; Ribero S.
File in questo prodotto:
File Dimensione Formato  
jcm-10-01283.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 923.46 kB
Formato Adobe PDF
923.46 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/851834
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 7
social impact